Teyi Pharmaceutical GroupLtd Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Teyi Pharmaceutical GroupLtd'in kazançlarının artacağı tahmin edilmektedir. EPS'nin büyümesi yıllık 48.4% oranında azalması beklenmektedir.

Anahtar bilgiler

47.2%

Kazanç büyüme oranı

48.4%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	18.9%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	17.7%
Analist kapsamı	Low
Son güncelleme	20 May 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Can Stay On Top Of Its Debt

Jun 06

Why Teyi Pharmaceutical GroupLtd's (SZSE:002728) Shaky Earnings Are Just The Beginning Of Its Problems

Apr 26

Teyi Pharmaceutical Group Co.,Ltd's (SZSE:002728) Shares Bounce 29% But Its Business Still Trails The Market

Mar 06

Here's Why We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Is Well Worth Watching

Feb 27

Kazanç ve Gelir Büyüme Tahminleri

SZSE:002728 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
9/30/2024	778	71	-13	88	N/A
6/30/2024	843	104	-5	98	N/A
3/31/2024	928	157	42	132	N/A
12/31/2023	1,067	253	113	199	N/A
9/30/2023	1,049	269	223	317	N/A
6/30/2023	1,040	269	267	363	N/A
3/31/2023	996	238	282	372	N/A
12/31/2022	887	178	281	372	N/A
9/30/2022	816	122	136	216	N/A
6/30/2022	785	113	107	206	N/A
3/31/2022	758	131	98	207	N/A
1/1/2022	758	127	147	257	N/A
9/30/2021	725	118	146	258	N/A
6/30/2021	691	92	130	231	N/A
3/31/2021	652	63	116	213	N/A
12/31/2020	633	44	80	169	N/A
9/30/2020	668	66	35	143	N/A
6/30/2020	743	108	63	176	N/A
3/31/2020	852	155	105	221	N/A
12/31/2019	921	172	91	222	N/A
9/30/2019	939	168	51	213	N/A
6/30/2019	949	171	48	217	N/A
3/31/2019	926	171	44	209	N/A
12/31/2018	885	156	36	188	N/A
9/30/2018	828	146	69	166	N/A
6/30/2018	777	128	N/A	132	N/A
3/31/2018	739	112	N/A	102	N/A
12/31/2017	687	106	N/A	103	N/A
9/30/2017	689	110	N/A	72	N/A
6/30/2017	680	105	N/A	103	N/A
3/31/2017	650	94	N/A	154	N/A
12/31/2016	656	95	N/A	101	N/A
9/30/2016	648	85	N/A	145	N/A
6/30/2016	631	84	N/A	67	N/A
3/31/2016	584	80	N/A	7	N/A
12/31/2015	517	81	N/A	69	N/A
9/30/2015	419	78	N/A	23	N/A
6/30/2015	356	74	N/A	68	N/A
3/31/2015	355	78	N/A	59	N/A
12/31/2014	345	80	N/A	57	N/A
9/30/2014	347	82	N/A	97	N/A
6/30/2014	345	85	N/A	N/A	N/A
3/31/2014	337	82	N/A	N/A	N/A
12/31/2013	343	81	N/A	74	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 002728 'nin tahmini kazanç büyümesi (yıllık 47.2% ) tasarruf oranının ( 2.8% ) üzerindedir.

Kazançlar ve Piyasa: 002728 şirketinin kazançlarının (yıllık 47.2% ) CN pazarından (yıllık 26.3% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 002728 şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: 002728 şirketinin gelirinin CN pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: 002728 şirketinin gelirinin yıllık 20% oranından daha hızlı artacağının tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 002728 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 17.7 %).

Teyi Pharmaceutical GroupLtd Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 22%

Teyi Pharmaceutical Group Co.,Ltd to Report Q3, 2024 Results on Oct 26, 2024

Now 24% overvalued

Now 20% overvalued

Teyi Pharmaceutical Group Co.,Ltd to Report First Half, 2024 Results on Jul 19, 2024

Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) announces an Equity Buyback for CNY 120 million worth of its shares.

We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Can Stay On Top Of Its Debt

Why Teyi Pharmaceutical GroupLtd's (SZSE:002728) Shaky Earnings Are Just The Beginning Of Its Problems

Investor sentiment deteriorates as stock falls 15%

First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.33 in 1Q 2023)

Teyi Pharmaceutical Group Co.,Ltd to Report Q1, 2024 Results on Apr 20, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 22% overvalued

Teyi Pharmaceutical Group Co.,Ltd, Annual General Meeting, Mar 28, 2024

Teyi Pharmaceutical Group Co.,Ltd, Annual General Meeting, Mar 28, 2024

Teyi Pharmaceutical Group Co.,Ltd's (SZSE:002728) Shares Bounce 29% But Its Business Still Trails The Market

Here's Why We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Is Well Worth Watching

Investor sentiment deteriorates as stock falls 18%

High number of new and inexperienced directors

Teyi Pharmaceutical Group Co.,Ltd to Report Fiscal Year 2023 Results on Mar 08, 2024

Investor sentiment improves as stock rises 21%

Third quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.11 in 3Q 2022)

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.051 in 2Q 2022)

Teyi Pharmaceutical Group Co.,Ltd Announces Final Dividend on A Shares for the Year 2022, Payable on May 26, 2023

Teyi Pharmaceutical Group Co.,Ltd Approves Cash Dividend (Tax Included) for 2022

Full year 2022 earnings released: EPS: CN¥0.80 (vs CN¥0.62 in FY 2021)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 24%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.14 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.071 (vs CN¥0.17 in 2Q 2021)

High number of new directors

Teyi Pharmaceutical Group Co.,Ltd Announces Management Appointments

Investor sentiment improved over the past week

Teyi Pharmaceutical Group Co.,Ltd Announces Final Cash Dividend on A Shares for the Year 2021, Payable on May 10, 2022

First quarter 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.20 in 1Q 2021)

Investor sentiment deteriorated over the past week

Teyi Pharmaceutical Group Co.,Ltd Approves Cash Dividend (Tax Included) for the Year 2021

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.007 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.021 in 2Q 2020)

Investor sentiment improved over the past week

Teyi Pharmaceutical Group Co.,Ltd Proposes 2020 Final Profit Distribution Plan, Payable on 03 June 2021

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.22 (vs CN¥0.85 in FY 2019)

New 90-day low: CN¥10.51

New 90-day low: CN¥12.39

Teyi Pharmaceutical Group Co.,Ltd to Report Q3, 2020 Results on Oct 27, 2020

Yueke Zhijing cancelled the acquisition of 5% stake in Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) from Xu Weigao, Xu Hengqing and Xu Lifang.

New 90-day low - CN¥13.52

Earnings released

Teyi Pharmaceutical Group Co.,Ltd to Report First Half, 2020 Results on Aug 26, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin